A government coordination commission has been established in Georgia to regulate prices within the consumer market. The creation of this commission was prompted by Prime Minister Irakli Kobakhidze’s statement highlighting that food prices in Georgia are higher than those in Europe.
After the commission held meetings with the food production sector, the scope of the issue deepened, and discussions on price control mechanisms expanded to the medication sector. Within the framework of the commission, working meetings have already been held with representatives of the pharmaceutical industry.
The state regulation of medication prices is one of the most complex and controversial issues in modern healthcare policy. This mechanism is often vital, especially in developing countries like Georgia; however, such state policies carry both obvious positive effects and hidden economic risks.
This article reviews the expected positive and negative effects that price controls on medications may bring to both the population and the sector as a whole.
Positive Outcomes
The primary and unconditional advantage of regulation is the alleviation of the financial burden on the population, especially for chronic patients. This mechanism allows the state to directly protect citizens from high expenditures on medications.
-
Affordability: Establishing price ceilings—for example, through reference pricing—makes medications more accessible to low-income populations.
-
Market Predictability: State control can ensure market predictability and eliminate sharp, speculative price hikes. This sense of stability is important for both consumers and the insurance sector, as it allows for better budget planning.
-
Generic Adoption: Regulations often push the market toward adopting cheaper but effective analogs, known as generics. This process contributes to the optimization of the overall healthcare budget and a more efficient distribution of resources.
Negative Outcomes
On the other hand, overly strict intervention may produce the opposite effect and ultimately harm the patient. Excessive market regulation often creates barriers that negatively impact the quality of medical services in the long run.
-
Lack of Innovation: One of the main challenges is a shortage of innovative medications. International pharmaceutical giants often avoid introducing new-generation drugs to countries where price caps are too low. As the process becomes economically non-viable for them, patients’ access to the latest and most effective treatments is significantly restricted.
-
Risk of Shortages: If the state-mandated price is lower than the cost for the manufacturer or importer, the product may disappear from the market. In developing nations, this is a frequent cause of critical medication shortages.
-
Reduced R&D Investment: Regulations often lead to a reduction in Research and Development (R&D) investment. The pharmaceutical sector reinvests a large portion of its profits into the creation of new drugs and laboratory research. Artificially reducing profit margins directly affects the pace of medical science development.
